Liraglutide Indicated to Reduce Risk for Cardiovascular Events (FREE)
By Kelly Young
Edited by Susan Sadoughi, MD, and Andr é Sofair, MD, MPH
The type 2 diabetes drug liraglutide (Victoza) has received a new indication, …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Primary Care | Victoza